晚期鳞状细胞肺癌的当前与新兴治疗选择
本文综述晚期鳞状细胞肺癌(SqCLC)的治疗挑战与指南推荐方案,并评估新近获批药物(necitumumab、afatinib、nivolumab、pembrolizumab、atezolizumab)的生存获益,提出整合这些药物的治疗算法。
要点
- SqCLC患者中位生存较其他NSCLC亚型短约30%。
- 综述涵盖指南推荐及新获批药物的生存获益。
- 提出整合新药的治疗算法供临床参考。
核心结论
- 晚期SqCLC治疗具挑战性,需结合患者特征与指南推荐及新药制定策略。
研究设计与样本
- 综述性文章,回顾晚期SqCLC的指南推荐治疗、新获批药物及在研免疫治疗证据。
主要发现
- 晚期SqCLC患者中位生存约比其他NSCLC亚型短30%。
- 综述评估了necitumumab、afatinib、nivolumab、pembrolizumab、atezolizumab在晚期SqCLC人群中的生存获益。
临床怎么用
- 可参考文中提出的治疗算法,将新获批药物纳入晚期SqCLC治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.
引用
- Socinski MA, Obasaju C, Gandara D, et al. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 29175116. doi:10.1016/j.jtho.2017.11.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。